#tradingfloorai | #AZN | #Approvals | 

AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for treating a specific type of breast cancer. This approval expands the use of Enhertu to an earlier treatment setting and a broader patient population. The Phase III DESTINY-Breast06 trial showed that Enhertu significantly improved progression-free survival compared to chemotherapy in patients with HER2-low or HER2-ultralow metastatic breast cancer. The trial results led to the FDA granting Priority Review and Breakthrough Therapy Designation. Enhertu is a HER2-directed antibody-drug conjugate, and its approval highlights the importance of testing metastatic breast cancer tumors for HER2 status to identify eligible patients for treatment following endocrine therapy. The financial arrangements between AstraZeneca and Daiichi Sankyo for Enhertu sales and milestones are also mentioned in the text. Read More@: